Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INCNBIX · Entity 2655 | Chief Regulatory Officer | September 11, 2026 | September 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEUROCRINE BIOSCIENCES INC
Report date September 11, 2026 · Filed September 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,289 |
Ending reported balance
After 2026-09-11 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-11 · Grant · Acquired 4,483 · Balance 20,708 F1: The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026. Row 2 · 2026-09-11 · Tax withholding · Disposed 2,419 · Balance 18,289 F2: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026.
F2: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 31, 2024 Filed Jan 3, 2025 21:23 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 272 | $0.00 Strike: $79.02 | $0.00 |
DisclosureSEC source: 0000914475-25-000002 · wk-form4_1735939418.xml · derivative · entry 3 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,718 Underlying: Common Stock · 272 shares Expires 2032-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option was granted January 31, 2022 and vests in 48 equal monthly installments beginning February 28, 2022. These options will expire ten years from the date of grant on January 31, 2032. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 21:23 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 272 | $138.10 | $37,563.20 |
DisclosureSEC source: 0000914475-25-000002 · wk-form4_1735939418.xml · nonDerivative · entry 2 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,507 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2023. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 21:23 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 272 | $79.02 | $21,493.44 |
DisclosureSEC source: 0000914475-25-000002 · wk-form4_1735939418.xml · nonDerivative · entry 1 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,779 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 17, 2024 Filed Dec 19, 2024 21:37 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 1,091 | $0.00 Strike: $79.02 | $0.00 |
DisclosureSEC source: 0000914475-24-000224 · wk-form4_1734644255.xml · derivative · entry 3 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,990 Underlying: Common Stock · 1,091 shares Expires 2032-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option was granted January 31, 2022 and vests in 48 equal monthly installments beginning February 28, 2022. These options will expire ten years from the date of grant on January 31, 2032. Read SEC document |
| December 17, 2024 Filed Dec 19, 2024 21:37 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,091 | $135.00 | $147,285.00 |
DisclosureSEC source: 0000914475-24-000224 · wk-form4_1734644255.xml · nonDerivative · entry 2 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,507 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2023. Read SEC document |
| December 17, 2024 Filed Dec 19, 2024 21:37 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 1,091 | $79.02 | $86,210.82 |
DisclosureSEC source: 0000914475-24-000224 · wk-form4_1734644255.xml · nonDerivative · entry 1 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,598 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 13, 2024 Filed Aug 15, 2024 21:06 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 3,043 | $0.00 Strike: $103.52 | $0.00 |
DisclosureSEC source: 0000914475-24-000191 · wk-form4_1723755955.xml · derivative · entry 4 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,049 Underlying: Common Stock · 3,043 shares Expires 2033-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2023 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| August 13, 2024 Filed Aug 15, 2024 21:06 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 4,100 | $150.08 | $615,333.33 |
DisclosureSEC source: 0000914475-24-000191 · wk-form4_1723755955.xml · nonDerivative · entry 3 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,507 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2023. F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $150.00 to $150.28. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 13, 2024 Filed Aug 15, 2024 21:06 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 3,043 | $150.13 | $456,847.11 |
DisclosureSEC source: 0000914475-24-000191 · wk-form4_1723755955.xml · nonDerivative · entry 2 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,607 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2023. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $150.00 to $150.44. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 13, 2024 Filed Aug 15, 2024 21:06 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 3,043 | $103.52 | $315,011.36 |
DisclosureSEC source: 0000914475-24-000191 · wk-form4_1723755955.xml · nonDerivative · entry 1 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,650 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 06, 2024 Filed Aug 8, 2024 21:16 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 273 | $0.00 Strike: $79.02 | $0.00 |
DisclosureSEC source: 0000914475-24-000189 · wk-form4_1723151810.xml · derivative · entry 3 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,081 Underlying: Common Stock · 273 shares Expires 2032-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option was granted January 31, 2022 and vests in 48 equal monthly installments beginning February 28, 2022. These options will expire ten years from the date of grant on January 31, 2032. Read SEC document |
| August 06, 2024 Filed Aug 8, 2024 21:16 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 273 | $147.70 | $40,322.10 |
DisclosureSEC source: 0000914475-24-000189 · wk-form4_1723151810.xml · nonDerivative · entry 2 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,607 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2023. Read SEC document |
| August 06, 2024 Filed Aug 8, 2024 21:16 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 273 | $79.02 | $21,572.46 |
DisclosureSEC source: 0000914475-24-000189 · wk-form4_1723151810.xml · nonDerivative · entry 1 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,880 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 16, 2024 Filed Jul 18, 2024 21:00 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 1,557 | $0.00 Strike: $103.52 | $0.00 |
DisclosureSEC source: 0000914475-24-000174 · wk-form4_1721336394.xml · derivative · entry 7 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,092 Underlying: Common Stock · 1,557 shares Expires 2033-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2023 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| July 16, 2024 Filed Jul 18, 2024 21:00 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 400 | $0.00 Strike: $103.52 | $0.00 |
DisclosureSEC source: 0000914475-24-000174 · wk-form4_1721336394.xml · derivative · entry 6 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,649 Underlying: Common Stock · 400 shares Expires 2033-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2023 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| July 16, 2024 Filed Jul 18, 2024 21:00 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 900 | $150.04 | $135,036.00 |
DisclosureSEC source: 0000914475-24-000174 · wk-form4_1721336394.xml · nonDerivative · entry 5 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,607 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2023 F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $150.00 to $150.18. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| July 16, 2024 Filed Jul 18, 2024 21:00 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,557 | $150.00 | $233,550.00 |
DisclosureSEC source: 0000914475-24-000174 · wk-form4_1721336394.xml · nonDerivative · entry 4 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,507 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2023 Read SEC document |
| July 16, 2024 Filed Jul 18, 2024 21:00 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 1,557 | $103.52 | $161,180.64 |
DisclosureSEC source: 0000914475-24-000174 · wk-form4_1721336394.xml · nonDerivative · entry 3 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,064 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 16, 2024 Filed Jul 18, 2024 21:00 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 400 | $150.10 | $60,041.00 |
DisclosureSEC source: 0000914475-24-000174 · wk-form4_1721336394.xml · nonDerivative · entry 2 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,507 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2023 F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $150.05 to $150.21. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| July 16, 2024 Filed Jul 18, 2024 21:00 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 400 | $103.52 | $41,408.00 |
DisclosureSEC source: 0000914475-24-000174 · wk-form4_1721336394.xml · nonDerivative · entry 1 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,907 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 01:09 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 272 | $0.00 Strike: $79.02 | $0.00 |
DisclosureSEC source: 0000914475-24-000164 · wk-form4_1719968973.xml · derivative · entry 3 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,354 Underlying: Common Stock · 272 shares Expires 2032-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option was granted January 31, 2022 and vests in 48 equal monthly installments beginning February 28, 2022. These options will expire ten years from the date of grant on January 31, 2032. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 01:09 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 272 | $138.11 | $37,565.92 |
DisclosureSEC source: 0000914475-24-000164 · wk-form4_1719968973.xml · nonDerivative · entry 2 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,507 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2023. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 01:09 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 272 | $79.02 | $21,493.44 |
DisclosureSEC source: 0000914475-24-000164 · wk-form4_1719968973.xml · nonDerivative · entry 1 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,779 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 31, 2024 Filed Jun 4, 2024 20:23 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 273 | $0.00 Strike: $79.02 | $0.00 |
DisclosureSEC source: 0000914475-24-000162 · wk-form4_1717532582.xml · derivative · entry 3 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,626 Underlying: Common Stock · 273 shares Expires 2032-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option was granted January 31, 2022 and vests in 48 equal monthly installments beginning February 28, 2022. These options will expire ten years from the date of grant on January 31, 2032. Read SEC document |
| May 31, 2024 Filed Jun 4, 2024 20:23 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 273 | $136.55 | $37,278.15 |
DisclosureSEC source: 0000914475-24-000162 · wk-form4_1717532582.xml · nonDerivative · entry 2 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,507 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2023. Read SEC document |
| May 31, 2024 Filed Jun 4, 2024 20:23 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 273 | $79.02 | $21,572.46 |
DisclosureSEC source: 0000914475-24-000162 · wk-form4_1717532582.xml · nonDerivative · entry 1 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,780 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 06, 2024 Filed May 8, 2024 20:26 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 273 | $79.02 Strike: $79.02 | $21,572.46 |
DisclosureSEC source: 0000914475-24-000119 · wk-form4_1715200000.xml · derivative · entry 3 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,899 Underlying: Common Stock · 273 shares Expires 2032-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option was granted January 31, 2022 and vests in 48 equal monthly installments beginning February 28, 2022. These options will expire ten years from the date of grant on January 31, 2032. Read SEC document |
| May 06, 2024 Filed May 8, 2024 20:26 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 273 | $140.55 | $38,370.15 |
DisclosureSEC source: 0000914475-24-000119 · wk-form4_1715200000.xml · nonDerivative · entry 2 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,507 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2023. Read SEC document |
| May 06, 2024 Filed May 8, 2024 20:26 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 273 | $79.02 | $21,572.46 |
DisclosureSEC source: 0000914475-24-000119 · wk-form4_1715200000.xml · nonDerivative · entry 1 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,780 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 20:44 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 272 | $79.02 Strike: $79.02 | $21,493.44 |
DisclosureSEC source: 0000914475-24-000100 · wk-form4_1712177026.xml · derivative · entry 3 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,172 Underlying: Common Stock · 272 shares Expires 2032-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option was granted January 31, 2022 and vests in 48 equal monthly installments beginning February 28, 2022. These options will expire ten years from the date of grant on January 31, 2032. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 20:44 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 272 | $137.30 | $37,345.60 |
DisclosureSEC source: 0000914475-24-000100 · wk-form4_1712177026.xml · nonDerivative · entry 2 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,507 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 20:44 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 272 | $79.02 | $21,493.44 |
DisclosureSEC source: 0000914475-24-000100 · wk-form4_1712177026.xml · nonDerivative · entry 1 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,779 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 21, 2024 Filed Mar 25, 2024 22:02 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 5,000 | $103.52 Strike: $103.52 | $517,600.00 |
DisclosureSEC source: 0000914475-24-000098 · wk-form4_1711404161.xml · derivative · entry 3 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,049 Underlying: Common Stock · 5,000 shares Expires 2033-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2023 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| March 21, 2024 Filed Mar 25, 2024 22:02 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 5,000 | $145.06 | $725,320.00 |
DisclosureSEC source: 0000914475-24-000098 · wk-form4_1711404161.xml · nonDerivative · entry 2 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,507 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Transactions at prices ranging from $145.00 to $145.24. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 21, 2024 Filed Mar 25, 2024 22:02 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 5,000 | $103.52 | $517,600.00 |
DisclosureSEC source: 0000914475-24-000098 · wk-form4_1711404161.xml · nonDerivative · entry 1 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,507 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 13, 2024 Filed Mar 15, 2024 21:15 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 3,000 | $106.02 Strike: $106.02 | $318,060.00 |
DisclosureSEC source: 0000914475-24-000090 · wk-form4_1710537319.xml · derivative · entry 3 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,367 Underlying: Common Stock · 3,000 shares Expires 2031-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option granted February 1, 2021 and vests at 25% upon first anniversary (February 1, 2022) and remaining 75% vesting in 36 equal monthly installments beginning on March 1, 2022. Read SEC document |
| March 13, 2024 Filed Mar 15, 2024 21:15 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 3,000 | $140.14 | $420,419.40 |
DisclosureSEC source: 0000914475-24-000090 · wk-form4_1710537319.xml · nonDerivative · entry 2 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,507 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $140.00 to $140.20. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 13, 2024 Filed Mar 15, 2024 21:15 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 3,000 | $106.02 | $318,060.00 |
DisclosureSEC source: 0000914475-24-000090 · wk-form4_1710537319.xml · nonDerivative · entry 1 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,507 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 11, 2024 Filed Mar 12, 2024 22:38 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 200 | $106.02 Strike: $106.02 | $21,204.00 |
DisclosureSEC source: 0000914475-24-000086 · wk-form4_1710283129.xml · derivative · entry 6 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,367 Underlying: Common Stock · 200 shares Expires 2031-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option granted February 1, 2021 and vests at 25% upon first anniversary (February 1, 2022) and remaining 75% vesting in 36 equal monthly installments beginning on March 1, 2022. Read SEC document |
| March 11, 2024 Filed Mar 12, 2024 22:38 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 200 | $140.00 | $28,000.00 |
DisclosureSEC source: 0000914475-24-000086 · wk-form4_1710283129.xml · nonDerivative · entry 4 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,507 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| March 11, 2024 Filed Mar 12, 2024 22:38 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 200 | $106.02 | $21,204.00 |
DisclosureSEC source: 0000914475-24-000086 · wk-form4_1710283129.xml · nonDerivative · entry 3 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,707 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 08, 2024 Filed Mar 12, 2024 22:38 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 1,800 | $106.02 Strike: $106.02 | $190,836.00 |
DisclosureSEC source: 0000914475-24-000086 · wk-form4_1710283129.xml · derivative · entry 5 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,567 Underlying: Common Stock · 1,800 shares Expires 2031-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option granted February 1, 2021 and vests at 25% upon first anniversary (February 1, 2022) and remaining 75% vesting in 36 equal monthly installments beginning on March 1, 2022. Read SEC document |
| March 08, 2024 Filed Mar 12, 2024 22:38 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,800 | $140.03 | $252,052.56 |
DisclosureSEC source: 0000914475-24-000086 · wk-form4_1710283129.xml · nonDerivative · entry 2 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,507 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $140.00 to $140.24. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 08, 2024 Filed Mar 12, 2024 22:38 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 1,800 | $106.02 | $190,836.00 |
DisclosureSEC source: 0000914475-24-000086 · wk-form4_1710283129.xml · nonDerivative · entry 1 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,307 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 29, 2024 Filed Mar 1, 2024 00:02 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 273 | $79.02 Strike: $79.02 | $21,572.46 |
DisclosureSEC source: 0000914475-24-000084 · wk-form4_1709251319.xml · derivative · entry 12 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,444 Underlying: Common Stock · 273 shares Expires 2032-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option was granted January 31, 2022 and vested in 48 equal monthly installments beginning February 28, 2022. These options will expire ten years from the date of grant on January 31, 2032. Read SEC document |
| February 29, 2024 Filed Mar 1, 2024 00:02 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 273 | $135.51 | $36,994.23 |
DisclosureSEC source: 0000914475-24-000084 · wk-form4_1709251319.xml · nonDerivative · entry 8 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,507 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| February 29, 2024 Filed Mar 1, 2024 00:02 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 273 | $79.02 | $21,572.46 |
DisclosureSEC source: 0000914475-24-000084 · wk-form4_1709251319.xml · nonDerivative · entry 7 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,780 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 00:02 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 1,544 | $79.02 Strike: $79.02 | $122,006.88 |
DisclosureSEC source: 0000914475-24-000084 · wk-form4_1709251319.xml · derivative · entry 11 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,717 Underlying: Common Stock · 1,544 shares Expires 2032-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option was granted January 31, 2022 and vested in 48 equal monthly installments beginning February 28, 2022. These options will expire ten years from the date of grant on January 31, 2032. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 00:02 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 2,500 | $79.02 Strike: $79.02 | $197,550.00 |
DisclosureSEC source: 0000914475-24-000084 · wk-form4_1709251319.xml · derivative · entry 10 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,261 Underlying: Common Stock · 2,500 shares Expires 2032-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option was granted January 31, 2022 and vested in 48 equal monthly installments beginning February 28, 2022. These options will expire ten years from the date of grant on January 31, 2032. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 00:02 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 2,500 | $79.02 Strike: $79.02 | $197,550.00 |
DisclosureSEC source: 0000914475-24-000084 · wk-form4_1709251319.xml · derivative · entry 9 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,761 Underlying: Common Stock · 2,500 shares Expires 2032-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option was granted January 31, 2022 and vested in 48 equal monthly installments beginning February 28, 2022. These options will expire ten years from the date of grant on January 31, 2032. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.